In Development
Novel Cardiac Biomarkers
B·R·A·H·M·S is currently developing patented biomarkers that may aid doctors in the diagnosis and prognosis of heart diseases.
Recent research on these biomarkers indicates great potential for the markers MR-proANP*, MR-proADM*, CT-proAVP (Copeptin)* and CT-proET-1* to improve clinical care in areas within cardiovascular disease.
According to the Centers for Disease Control and Prevention, heart disease is the most common cause of death in the US, killing more than 900,000 Americans every year. More than 70 million Americans live with some form of cardiovascular disease. An estimated 37% of the American public has two or more risk factors for heart disease.
Coronary heart disease is caused by atherosclerosis, the narrowing of the coronary arteries due to fatty build-ups of plaque. It's likely to produce angina pectoris (chest pain), heart attack or both. Approximately 16,000,000 people alive today—8,700,000 males and 7,300,000 females—have a history of heart attack, angina pectoris or both.
In 2005, an estimated 1.2 million Americans had a new or recurrent coronary attack. An estimated 500,000 people have a case of stable angina each year. About 310,000 people a year die of coronary attack in an Emergency Department or without being hospitalized.
Heart failure is a very common condition. About 5 million people in the United States have heart failure, with approximately 300,000 deaths each year. And the numbers are growing: Every year, another 550,000 people are diagnosed for the first time.
For more information, please call us or send a request to clinical.services@brahms-usa.com.
*MR-proANP, MR-proADM, CT-proAVP, and CT-ET-1 are currently available in the US as Research Use Only.